A study on the impact of @entity4433 genotype and platelet reactivity assay on XXXX undergoing PCI.

@entity1 @entity3076 @entity548 @entity4433 @entity2405 @entity1397 @entity3077 @entity299 @entity453
BACKGROUND: A thorough understanding of the @entity1 's genotype and their functional response to a medication is necessary for improving event free survival. Several outcome studies support this view particularly if the @entity1 is to be started on @entity1397 due to the prevalence of @entity1397 resistance. Such guided therapy has reduced the incidence of Major Adverse @entity299 (MACE) after stent implantation. METHODS: Between August 2013 and August 2014, 200 @entity1 with @entity453 undergoing percutaneous coronary intervention (PCI) were prescribed any one of the anti-platelet medications such as @entity1397 , @entity3076 or @entity3077 and offered testing to detect @entity4433 gene mutations along with a platelet reactivity assay (PRA). Intended outcome was modification of anti-platelet therapy defined as either dose escalation of @entity1397 or replacement of @entity1397 with @entity3076 or @entity3077 for the @entity1 in @entity1397 arm, and replacement of @entity3077 or @entity3076 with @entity1397 if those @entity1 were non-carrier of mutant genes and also if they demonstrated @entity548 tendencies in the @entity3077 and @entity3076 arms. CONCLUSION: @entity1397 resistance was observed to be 16.5% in our study population. PRA was useful in monitoring the efficacy of @entity2405 . By having this test, one can be safely maintained on @entity1397 in non-carriers, or with increased dose of @entity1397 in intermediate metabolizers or with newer drugs such as @entity3077 or @entity3076 in poor metabolizers. @entity1 on @entity3077 and @entity3076 identified as non-carriers of gene mutations for @entity1397 metabolism could be offered @entity1397 resulting in economic benefits to the @entity1 . @entity1 at high risk of @entity548 were also identified by the PRA.
